The Medicines and Healthcare products Regulatory Agency (MHRA) approved on Thursday, a product license for the medicine lecanemab for use in the early stages of Alzheimer's, after proving that it slow the progression of disease by 27 percent. The medicine works by removing the amyloid protein that accumulates in the brain of Alzheimer's patients and is administered via intravenous injection every two weeks for approximately 18 months, said the agency in a statement. The statement added that the medicine proved in treating patient who carry one or two of ApoE4 gene. Alzheimer's disease is the most common type of dementia and is one of the leading causes of death in the United Kingdom. This drug has also been licensed in the United States, Japan, and China. Source: Kuwait News Agency
Related Articles
Aggression commits 354 violations in Hodeida in 24 hours
The aggression forces committed 77 violations of the ceasefire agreement in Hodeida province over the past 24 hours, an official at the operations room to monitor the violations said on Tuesday. The official in the operations room told the Yemeni News Agency (Saba) that among the aggression forces violations were nine airstrikes by the spy […]
Canada voices concern over injuries among Jordanians working in hospital in Gaza
Canadian Foreign Minister Mélanie Joly voiced concern over the injuries sustained by Jordanians employed in the medical field in an attack that happened close to the Jordanian field hospital in Gaza.
“Jordan plays a vital humanitarian role through i…
Saudi Arabia Provides $90 Million Grant Tranche to Palestine for 2025
Amman: The Minister of Planning and International Cooperation and Acting Minister of Finance, Estephan Salameh, on Monday received a $90 million tranche of a Saudi grant to the State of Palestine, as part of the Kingdom’s continued support for 2025.
…